CareDx

Update in progress

CDNA (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryDiagnostics & Research

CareDx provides transplant-focused diagnostics and software to improve patient outcomes worldwide. Its tests include AlloSure dd-cfDNA for kidney, heart, and lung transplants; AlloMap Heart gene expression profiling; HeartCare and HistoMap Kidney for immune and rejection insights; AlloHeme for relapse prediction in AML/MDS; and a suite of HLA typing, graft monitoring, and transplant management tools (QTYPE, Olerup SSP, AlloSeq Tx/CFDNA/HCT, Allocell, XynQAPI, MedActionPlan, CareDx Pharmacy, AlloHome, HLA Data Systems). licensed with Illumina; founded 1998; Brisbane, CA.

Company score

Sentiment: 0.02; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.02; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.32; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.02; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNasdaqGM (NGM)
LocationUnited States
CEOMr. John Walter Hanna Jr.
Founded1998
Employees761
Websitecaredx.com

Identifiers

ISINUS14167L1035
FIGIBBG006JS5785
LEI549300NQOFKL9NON0U06
CUSIP14167L103
CIK0001217234